Despite missing the first COVID-19 vaccine wave, GlaxoSmithKline plc hopes to ride the cresting interest in the vaccine sector as it looks to maintain its leadership position in the field through the next decade. GSK aims to launch five new vaccines by 2026, management said during an investor overview on 23 June.
The growth outlook for vaccines centers on the expansion of its blockbuster Shingrix shingles vaccine, building out the meningitis franchise...